Drug Ther Bull. 1994 Feb 17;32(2):9-11. doi: 10.1136/dtb.1994.3229.
Until recently, protection against hepatitis A has depended on high standards of public health and hygiene, bolstered by selective passive immunisation of those at high risk of infection using human normal immunoglobulin (HNIG). The scope for prophylaxis changed in April 1992 with the introduction of a hepatitis A vaccine (Havrix--SmithKline Beecham), which offers active immunisation and so longer and more effective protection than HNIG. In this article we discuss the epidemiology of hepatitis A and the methods of prevention and control of the infection. We also appraise the vaccine and consider how it should be used.
直到最近，预防甲型肝炎还依赖于高标准的公共卫生和个人卫生，并通过使用人正常免疫球蛋白（HNIG）对高感染风险人群进行选择性被动免疫来加强防护。1992年4月，随着甲型肝炎疫苗（维康甲型肝炎疫苗——史克必成公司生产）的推出，预防的范围发生了变化，该疫苗提供主动免疫，因此比人正常免疫球蛋白的保护时间更长、效果更显著。在本文中，我们讨论了甲型肝炎的流行病学以及感染的预防和控制方法。我们还对该疫苗进行了评估，并考虑了其使用方式。
